Shareholders to Vote on Reverse Stock Split, Massive Dilutive Offerings, and Expanded Equity Plan

summarizeSummary

bioAffinity Technologies seeks shareholder approval for a reverse stock split to maintain Nasdaq listing, authorization for highly dilutive future offerings, and significant increases in share pools for warrants and equity plans, signaling urgent capital needs and potential for substantial shareholder dilution.

check_boxKey Events

• Proposed Reverse Stock Split

  The Board seeks shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-250, primarily to increase the per-share trading price and maintain compliance with Nasdaq's minimum bid price requirement.

• Authorization for Highly Dilutive Future Offerings

  Shareholders will vote on authorizing the issuance of up to 10 million shares of common stock (or equivalents) in one or more non-public offerings, with total aggregate consideration not exceeding $10,000,000. This represents a potential capital raise more than double the company's current market capitalization.

• Approval of Warrant & Preferred Stock Issuance and Anti-Dilution

  The company is seeking approval for the issuance of up to 271,500 shares upon the exercise of August 2025 Warrants (potentially yielding $2.9 million in proceeds) and for anti-dilution provisions on these warrants and Series B Preferred Stock, which could lead to the issuance of an additional 497,504 shares at lower floor prices ($4.50 and $3.00 respectively) if triggered by future dilutive issuances.

• Significant Increase in Equity Incentive Plan

  A proposal to amend the 2024 Equity Incentive Plan to increase the number of shares reserved for issuance from 66,666 to 1,000,000 shares, representing approximately 20% of the company's fully diluted outstanding shares.

auto_awesomeAnalysis

bioAffinity Technologies is presenting a series of critical proposals to shareholders, primarily aimed at addressing significant financial challenges and maintaining its Nasdaq listing. The proposed reverse stock split, ranging from 1-for-2 to 1-for-250, is a strong indicator of the company's struggle to meet the minimum bid price requirement. Concurrently, the request for authorization to conduct future non-public offerings of up to $10 million, which is more than double the current market capitalization, highlights an urgent need for capital and signals substantial potential dilution for existing shareholders. Furthermore, the company is seeking approval for the issuance of shares related to prior warrant exercises and for anti-dilution provisions on existing warrants and preferred stock, which could lead to further dilution at potentially lower prices. The proposed increase in the equity incentive plan by over 14 times also adds to the dilutive pressure. While these measures are presented as necessary for the company's continued operation and growth, their combined effect points to a highly precarious financial situation and significant risk for current investors.